Please provide your email address to receive an email when new articles are posted on . A 54-year-old man was referred in late 2014 for a consultation for corneal transplant surgery in the left eye.

Credit: Glaukos. Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.

Please provide your email address to receive an email when new articles are posted on . In advanced cases that may normally require a corneal transplant, Beckman said cross-linking with scleral lenses ...

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for ...

SHERBORN, Mass.--(BUSINESS WIRE)--CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking Phase ...

A pediatric subgroup from a pivotal phase 3 trial randomized 2:1 showed epithelium-on oxygen-enriched CXL improved Kmax at 6 ...

SHREVEPORT, La. -- Cross linking is is an eye treatment only offered in this area at the Willis Knighton Eye Institute, and it's performed as a community service. Cross linking is for patients with an ...

Keratoconus is a progressive, noninflammatory corneal disorder that causes corneal thinning and irregularity, resulting in impaired vision. It typically begins in adolescence and progresses slowly ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...